Plain-English translation of NCT06409832 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Migraine research guide →This research study is testing rimegepant, a newer medication designed to prevent migraines before they start. Rimegepant works by blocking a specific pain pathway in the brain that plays a role in migraines. This study will track how well the medication prevents migraines and how patients tolerate it over two years of regular use.
While early studies showed this medication works well for migraine prevention, researchers want to see how it performs in everyday clinical practice with real patients in different locations. This will help doctors understand whether the treatment is truly helpful and safe for people living with regular migraines.
You likely qualify if…
You likely don't qualify if…
You would take the medication as a small dissolving tablet every other day for up to two years. You'll visit the clinic at the start and then every three months, where staff will check on your progress. Throughout the study, you'll keep a simple headache diary to track your migraines, and complete brief questionnaires to help researchers understand how the medication is affecting your quality of life and disability.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Italy
Sponsor
University of Florence
Collaborators
IRCCS National Neurological Institute "C. Mondino" Foundation, Società Italiana per lo Studio delle Cefalee
Enrollment target
~100 participants
Started
March 2024
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Luigi F Iannone, MD
University of Florence
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.